The results: New infections occurred in 51 of the 8,197 given vaccine and in 74 of the 8,198 who received dummy shots. That worked out to a 31 percent lower risk of infection for the vaccine group. Two of the infected participants who received the placebo died.
The vaccine had no effect on levels of HIV in the blood for those who did become infected. That had been another goal of the study — seeing whether the vaccine could limit damage to the immune system and help keep infected people from developing full-blown AIDS.
That result is "one of the most important and intriguing findings of this trial," Fauci said. It suggests that the signs scientists have been using to gauge whether a vaccine was actually giving protection may not be valid.
SHOOT: Since those who were vaccinated and infected showed no difference in levels of HIV, I'd be inclined to question the effectiveness here. 31% lower infection risk? Nope, not sure I buy it.
The vaccine — a combination of two previously unsuccessful vaccines — cut the risk of becoming infected with HIV by more than 31 percent in the world's largest AIDS vaccine trial of more than 16,000 volunteers in Thailand, researchers announced Thursday in Bangkok.
Even though the benefit is modest, "it's the first evidence that we could have a safe and effective preventive vaccine," Col. Jerome Kim told The Associated Press. He helped lead the study for the U.S. Army, which sponsored it with the National Institute of Allergy and Infectious Diseases.
Even a marginally helpful vaccine could have a big impact. Every day, 7,500 people worldwide are newly infected with HIV; 2 million died of AIDS in 2007, UNAIDS estimates.
Participants volunteered for the study and were told about the potential risks associated with receiving the experimental vaccine before agreeing to participate.
|
No comments:
Post a Comment